Perceived stigma among patients receiving antiretroviral treatment: a prospective randomised trial comparing an m-DOT strategy with standard-of-care in Kenya.
View/ Open
Date
2010Author
Kaai, S
Bullock, S
Sarna, A
Chersich, M
Luchters, S
Geibel, S
Munyao, P
Mandaliya, K
Temmerman, M
Rutenburg, N
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
HIV and AIDS remain highly stigmatised. Modified directly observed therapy (m-DOT) supports antiretroviral treatment (ART) adherence but little is known about its association with perceived stigma in resource-constrained settings. In 2003, 234 HIV-infected adults enrolled in a two-arm randomised trial comparing a health centre-based m-DOT strategy with standard self-administration of ART. Data on perceived stigma were collected using Berger's HIV stigma scale prior to starting ART and after 12 months. This was a secondary analysis to examine whether perceived stigma was related to treatment delivery. Perceived stigma scores declined after 12 months of treatment from a mean of 44.9 (sd=7.6) to a mean of 41.4 (sd=7.7), (t=6.14, P<0.001). No differences were found between the mean scores of participants in both study arms. Also, no difference in scores was detected using GLM, controlling for socio-demographic characteristics and baseline scores. Findings indicate that a well managed clinic-based m-DOT does not increase perceived HIV-related stigma
URI
http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/21409296http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/40648
Citation
SAHARA J. 2010 Aug;7(2):62-70.Collections
- Faculty of Health Sciences (FHS) [10377]